Cargando…
Effects of enhancer of zeste homolog 2 and mucin 1 expressions on treatment response in breast cancer
OBJECTIVE: Breast cancer is the most common malignancy in women. In the treatment of these patients, pathological complete response is defined as the absence of invasive cancer in breast or lymph node tissue after the completion of neoadjuvant chemotherapy. In this study, we aimed to investigate the...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Associação Médica Brasileira
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937598/ https://www.ncbi.nlm.nih.gov/pubmed/36820722 http://dx.doi.org/10.1590/1806-9282.20221123 |
_version_ | 1784890457300402176 |
---|---|
author | Yetişir, Abdullah Evren Paydaş, Semra Büyükşimşek, Mahmut Oğul, Ali Yaprak, Özge Zorludemir, Suzan Ergin, Melek Kolsuz, İrem Kidi, Mehmet Mutlu |
author_facet | Yetişir, Abdullah Evren Paydaş, Semra Büyükşimşek, Mahmut Oğul, Ali Yaprak, Özge Zorludemir, Suzan Ergin, Melek Kolsuz, İrem Kidi, Mehmet Mutlu |
author_sort | Yetişir, Abdullah Evren |
collection | PubMed |
description | OBJECTIVE: Breast cancer is the most common malignancy in women. In the treatment of these patients, pathological complete response is defined as the absence of invasive cancer in breast or lymph node tissue after the completion of neoadjuvant chemotherapy. In this study, we aimed to investigate the relationship of enhancer of zeste homolog 2 and mucin 1 expressions with pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy. METHODS: A total of 151 patients were included in the study. Enhancer of zeste homolog 2 and mucin 1 expressions were evaluated in the biopsy materials pre-neoadjuvant chemotherapy and post-neoadjuvant chemotherapy surgical material, and their relationship with pathological complete response was investigated. RESULTS: The pathological complete response rates were significantly higher among the hormone receptor-negative patients, those with a high Ki-67 score, and patients with HER2-positive. Higher pathological complete response rates were obtained from patients with enhancer of zeste homolog 2 expression positivity pre-neoadjuvant chemotherapy. In addition, after neoadjuvant chemotherapy, enhancer of zeste homolog 2 expression was found to be completely negative in materials with pathological complete response; that is, in breast tissues considered to be tumor-free. While there was no significant relationship between mucin 1 expression and pathological complete response pre-neoadjuvant chemotherapy, mucin 1 expression was determined to significantly differ between the tissues with and without pathological complete response among the surgical materials examined. CONCLUSION: In our study investigating the relationship between enhancer of zeste homolog 2 and mucin 1 expression and pathological complete response in patients who received neoadjuvant chemotherapy, we found that enhancer of zeste homolog 2 expression could be used as a predictive marker for pathological complete response. However, mucin 1 expression was not associated with pathological complete response. |
format | Online Article Text |
id | pubmed-9937598 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Associação Médica Brasileira |
record_format | MEDLINE/PubMed |
spelling | pubmed-99375982023-02-18 Effects of enhancer of zeste homolog 2 and mucin 1 expressions on treatment response in breast cancer Yetişir, Abdullah Evren Paydaş, Semra Büyükşimşek, Mahmut Oğul, Ali Yaprak, Özge Zorludemir, Suzan Ergin, Melek Kolsuz, İrem Kidi, Mehmet Mutlu Rev Assoc Med Bras (1992) Original Article OBJECTIVE: Breast cancer is the most common malignancy in women. In the treatment of these patients, pathological complete response is defined as the absence of invasive cancer in breast or lymph node tissue after the completion of neoadjuvant chemotherapy. In this study, we aimed to investigate the relationship of enhancer of zeste homolog 2 and mucin 1 expressions with pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy. METHODS: A total of 151 patients were included in the study. Enhancer of zeste homolog 2 and mucin 1 expressions were evaluated in the biopsy materials pre-neoadjuvant chemotherapy and post-neoadjuvant chemotherapy surgical material, and their relationship with pathological complete response was investigated. RESULTS: The pathological complete response rates were significantly higher among the hormone receptor-negative patients, those with a high Ki-67 score, and patients with HER2-positive. Higher pathological complete response rates were obtained from patients with enhancer of zeste homolog 2 expression positivity pre-neoadjuvant chemotherapy. In addition, after neoadjuvant chemotherapy, enhancer of zeste homolog 2 expression was found to be completely negative in materials with pathological complete response; that is, in breast tissues considered to be tumor-free. While there was no significant relationship between mucin 1 expression and pathological complete response pre-neoadjuvant chemotherapy, mucin 1 expression was determined to significantly differ between the tissues with and without pathological complete response among the surgical materials examined. CONCLUSION: In our study investigating the relationship between enhancer of zeste homolog 2 and mucin 1 expression and pathological complete response in patients who received neoadjuvant chemotherapy, we found that enhancer of zeste homolog 2 expression could be used as a predictive marker for pathological complete response. However, mucin 1 expression was not associated with pathological complete response. Associação Médica Brasileira 2023-02-17 /pmc/articles/PMC9937598/ /pubmed/36820722 http://dx.doi.org/10.1590/1806-9282.20221123 Text en https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Yetişir, Abdullah Evren Paydaş, Semra Büyükşimşek, Mahmut Oğul, Ali Yaprak, Özge Zorludemir, Suzan Ergin, Melek Kolsuz, İrem Kidi, Mehmet Mutlu Effects of enhancer of zeste homolog 2 and mucin 1 expressions on treatment response in breast cancer |
title | Effects of enhancer of zeste homolog 2 and mucin 1 expressions on treatment response in breast cancer |
title_full | Effects of enhancer of zeste homolog 2 and mucin 1 expressions on treatment response in breast cancer |
title_fullStr | Effects of enhancer of zeste homolog 2 and mucin 1 expressions on treatment response in breast cancer |
title_full_unstemmed | Effects of enhancer of zeste homolog 2 and mucin 1 expressions on treatment response in breast cancer |
title_short | Effects of enhancer of zeste homolog 2 and mucin 1 expressions on treatment response in breast cancer |
title_sort | effects of enhancer of zeste homolog 2 and mucin 1 expressions on treatment response in breast cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937598/ https://www.ncbi.nlm.nih.gov/pubmed/36820722 http://dx.doi.org/10.1590/1806-9282.20221123 |
work_keys_str_mv | AT yetisirabdullahevren effectsofenhancerofzestehomolog2andmucin1expressionsontreatmentresponseinbreastcancer AT paydassemra effectsofenhancerofzestehomolog2andmucin1expressionsontreatmentresponseinbreastcancer AT buyuksimsekmahmut effectsofenhancerofzestehomolog2andmucin1expressionsontreatmentresponseinbreastcancer AT ogulali effectsofenhancerofzestehomolog2andmucin1expressionsontreatmentresponseinbreastcancer AT yaprakozge effectsofenhancerofzestehomolog2andmucin1expressionsontreatmentresponseinbreastcancer AT zorludemirsuzan effectsofenhancerofzestehomolog2andmucin1expressionsontreatmentresponseinbreastcancer AT erginmelek effectsofenhancerofzestehomolog2andmucin1expressionsontreatmentresponseinbreastcancer AT kolsuzirem effectsofenhancerofzestehomolog2andmucin1expressionsontreatmentresponseinbreastcancer AT kidimehmetmutlu effectsofenhancerofzestehomolog2andmucin1expressionsontreatmentresponseinbreastcancer |